Endoscopic biliary recanalization by using a needle catheter in patients with complete ligation or stricture of the bile duct: safety and feasibility of a novel technique (with videos).

Kapil Gupta,Dayse P. Aparicio,M. Freeman,C. Sakai,José L B Paione,E. Artifon

DOI: https://doi.org/10.1016/j.gie.2011.03.1234

IF: 10.396

2011-08-01

Gastrointestinal Endoscopy

Abstract:

What problem does this paper attempt to address?

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.

J. Rahal,C. Urban,D. Horn,K. Freeman,S. Segal-maurer,James Maurer,N. Mariano,Sheila Marks,J. Burns,Dana Dominick,Mimi Lim

DOI: https://doi.org/10.1001/JAMA.280.14.1233

1998-10-14

Abstract:CONTEXT Resistance to most or all cephalosporin antibiotics in Klebsiella species has developed in many European and North American hospitals during the past 2 decades. OBJECTIVE To determine if restriction of use of the cephalosporin class of antibiotics would reduce the incidence of patient infection or colonization by cephalosporin-resistant Klebsiella. DESIGN A before-after comparative 2-year trial. SETTING A 500-bed, university-affiliated community hospital in Queens, NY. PATIENTS All adult medical and surgical hospital inpatients. INTERVENTION A new antibiotic guideline excluded the use of cephalosporins except for pediatric infection, single-dose surgical prophylaxis, acute bacterial meningitis, spontaneous bacterial peritonitis, and outpatient gonococcal infection. All other cephalosporin use required prior approval by the infectious disease section. MAIN OUTCOME MEASURE Incidence of patient infection or colonization by ceftazidime-resistant Klebsiella during 1995 (control period) compared with 1996 (intervention period). RESULTS An 80.1% reduction in hospital-wide cephalosporin use occurred in 1996 compared with 1995. This was accompanied by a 44.0% reduction in the incidence of ceftazidime-resistant Klebsiella infection and colonization throughout the medical center (P<.01), a 70.9% reduction within all intensive care units (P<.001), and an 87.5% reduction within the surgical intensive care unit (P<.001). A concomitant 68.7% increase in the incidence of imipenem-resistant Pseudomonas aeruginosa occurred throughout the medical center (P<.01). All such isolates except one were susceptible to other antibiotics. CONCLUSION Extensive cephalosporin class restriction significantly reduced nosocomial, plasmid-mediated, cephalosporin-resistant Klebsiella infection and colonization. This occurred at the price of increased imipenem resistance in P aeruginosa, which remained susceptible to other agents. Thus, an overall reduction in multiply-resistant pathogens was achieved within 1 year.
Ginkgo biloba Extract EGb 761® or Pentoxifylline for the Treatment of Sudden Deafness: A Randomized, Reference-controlled, Double-blind Study

H. Weidauer,CH. REISSER

DOI: https://doi.org/10.1080/oto.121.5.579.584

2001-01-01

Abstract:In a randomized, prospective, double-blind study involving 72 patients, the therapeutic efficacy of ginkgo extract EGb 761® (n =37) was compared to that of pentoxifylline (n =35) for the treatment of sudden deafness. The two therapeutic schedules were equally well tolerated and showed a statistically significant equivalence in improvement or in return to normal of the auditory thresholds in the two patient groups. Furthermore, no differences were found between the treatment groups with regard to the criteria for a return to normal of speech discrimination and reduction of the tinnitus which arose at the same time as the sudden hearing loss. The patient's subjective assessment of the treatment with regard to improvement in hearing and reduction in tinnitus suggested that Ginkgo biloba extract was more beneficial than pentoxifylline. In summary, it was shown that treatment of sudden deafness with ginkgo special extract EGb 761 was as effective as treatment with pentoxifylline.

otorhinolaryngology
AN EVALUATION OF PULP SLUDGE AS A COMPONENT IN MANUFACTURED TOPSOILS

A. Carpenter,L. Zibilske

Abstract:Pulp and paper mill sludges have many attributes which, when utilized as a soil amendment, can improve soil fertility and overall soil quality. The primary objective of this study was to evaluate the use of pulp sludge as the organic matter component in a manufactured topsoil. Seven manufactured topsoils, containing 5.1, 8.8, 9.6, 10.9, or 13.8% pulp sludge and 0, 8.4, or 20.7% flume grit on a dry weight basis, were blended and applied to an abandoned gravel pit. These manufactured topsoils and a control topsoil were evaluated for changes in soil chemistry, impacts on soil solution chemistry and effectiveness as a growing medium for a grass conservation mix and for hybrid poplars. Results from a laboratory incubation study indicated that net N mineralization in the manufactured topsoils ranged from 9.7 to 18.2% of TKN after 105 days. Soil NO3 levels up to 20 times that of the control topsoil within four months of topsoil placement in the field plots confirmed that N mineralization was rapid in the manufactured topsoils. The addition of flume grit to the topsoil blends in some cases reduced the rate of N mineralization, presumably by increasing the C:N ratios of the topsoils. Soil CEC, pH and P availability were all positively correlated to pulp sludge loading rate in the manufactured topsoils. The greatest impacts of the manufactured topsoils on soil solution were in the first collection period following topsoil placement. Nitrate and Ca were the dominant ions in solution during this period. The manufactured topsoils improved both grass and tree yields relative to the control topsoil. Total grass yields from three harvests in the 15 months following topsoil placement ranged from 3.87 to 7.26 Mg ha in the manufactured topsoils. For grass plots, yields were positively correlated to soil NO3 levels, while hybrid poplar growth responses were largely controlled by the growth of herbaceous vegetation within the tree plots. Results from this study demonstrate that the use of pulp sludge in manufactured topsoils can improve soil fertility and create a favorable growing medium for both conservation grass mixes and hybrid poplars.
Pharmacologic treatments in preclinical tinnitus models with special focus on Ginkgo biloba leaf extract EGb 761®

Stephan W Barth,Martin D Lehner,Gunnar P H Dietz,Holger Schulze

DOI: https://doi.org/10.1016/j.mcn.2021.103669

Abstract:Tinnitus is defined as the perception of sound in the absence of external acoustic stimuli. Frequent comorbidities or associated factors are depression, anxiety, concentration problems, insomnia, resignation, helplessness, headache, bruxism, or social isolation, just to name a few. Although many therapeutic approaches have already been tested with varying success, there still is no cure available for tinnitus. The search for an effective treatment has been hampered by the fact that the mechanisms of tinnitus development are still not fully understood, although several models are available and discussed in this review. Our review will give a brief overview about preclinical models, presenting the heterogeneity of tinnitus sub-types depending on the different inner ear and brain structures involved in tinnitus etiology and pathogenesis. Based on these models we introduce the different target structures and transmitter systems implicated in tinnitus development and provide an extensive overview on preclinical drug-based therapeutic approaches that have been explored in various animal models. As the special extract from Ginkgo biloba leaves EGb 761® has been the most widely tested drug in both non-clinical tinnitus models as well as in clinical trials, a special focus will be given to EGb 761®. The efficacy of terpene lactones, flavone glycosides and proanthocyanidines with their distinct contribution to the overall efficacy profile of the multi-constituent drug EGb 761® will be discussed.
Protective Effects of Ginkgo biloba Extract EGb 761 against Noise Trauma-Induced Hearing Loss and Tinnitus Development

Konstantin Tziridis,Sabine Korn,Sönke Ahlf,Holger Schulze

DOI: https://doi.org/10.1155/2014/427298

2014-01-01

Neural Plasticity

Abstract:Noise-induced hearing loss (NIHL) and resulting comorbidities like subjective tinnitus are common diseases in modern societies. A substance shown to be effective against NIHL in an animal model is the Ginkgo biloba extract EGb 761. Further effects of the extract on the cellular and systemic levels of the nervous system make it a promising candidate not only for protection against NIHL but also for its secondary comorbidities like tinnitus. Following an earlier study we here tested the potential effectiveness of prophylactic EGb 761 treatment against NIHL and tinnitus development in the Mongolian gerbil . We monitored the effects of EGb 761 and noise trauma-induced changes on signal processing within the auditory system by means of behavioral and electrophysiological approaches. We found significantly reduced NIHL and tinnitus development upon EGb 761 application, compared to vehicle treated animals. These protective effects of EGb 761 were correlated with changes in auditory processing, both at peripheral and central levels. We propose a model with two main effects of EGb 761 on auditory processing, first, an increase of auditory brainstem activity leading to an increased thalamic input to the primary auditory cortex (AI) and second, an asymmetric effect on lateral inhibition in AI.

neurosciences
Preventive Effects of Ginkgo-Extract EGb 761® on Noise Trauma-Induced Cochlear Synaptopathy

Konstantin Tziridis,Holger Schulze

DOI: https://doi.org/10.3390/nu14153015

IF: 5.9

2022-07-22

Nutrients

Abstract:Noise trauma-induced loss of ribbon synapses at the inner hair cells (IHC) of the cochlea may lead to hearing loss (HL), resulting in tinnitus. We are convinced that a successful and sustainable therapy of tinnitus has to treat both symptom and cause. One of these causes may be the mentioned loss of ribbon synapses at the IHC of the cochlea. In this study, we investigated the possible preventive and curative effects of the Ginkgo biloba extract EGb 761® on noise-induced synaptopathy, HL, and tinnitus development in Mongolian gerbils (Meriones unguiculatus). To this end, 37 male animals received EGb 761® or placebo orally 3 weeks before (16 animals) or after (21 animals) a monaural acoustic noise trauma (2 kHz, 115 dB SPL, 75 min). Animals' hearing thresholds were determined by auditory brainstem response (ABR) audiometry. A possible tinnitus percept was assessed by the gap prepulse inhibition acoustic startle reflex (GPIAS) response paradigm. Synaptopathy was quantified by cochlear immunofluorescence histology, counting the ribbon synapses of 15 IHCs at 11 different cochlear frequency locations per ear. We found a clear preventive effect of EGb 761® on ribbon synapse numbers with the surprising result of a significant increase in synaptic innervation on the trauma side relative to placebo-treated animals. Consequently, animals treated with EGb 761® before noise trauma did not develop a significant HL and were also less affected by tinnitus compared to placebo-treated animals. On the other hand, we did not see a curative effect (EGb 761® treatment after noise trauma) of the extract on ribbon synapse numbers and, consequently, a significant HL and no difference in tinnitus development compared to the placebo-treated animals. Taken together, EGb 761® prevented noise-induced HL and tinnitus by protecting from noise trauma-induced cochlear ribbon synapse loss; however, in our model, it did not restore lost ribbon synapses.

nutrition & dietetics
Correction: The Critical Role of Partially Exposed N-Terminal Valine Residue in Stabilizing GH10 Xylanase from Bacillus sp.NG-27 under Poly-Extreme Conditions

A. Bhardwaj,S. Leelavathi,S. Mazumdar-Leighton,Amit Ghosh,S. Ramakumar,V. S. Reddy

DOI: https://doi.org/10.1371/annotation/aefbf6a4-298d-4173-907f-9c9a996249b2

IF: 3.7

2009-02-23

PLoS ONE

Abstract:
Reciprocal realization and modeling of textured images

A. Chiuso,A. Ferrante,G. Picci

DOI: https://doi.org/10.1109/CDC.2005.1583131

2005-12-12

Abstract:This paper attempts to view texture analysis and synthesis in image processing as a problem of realization and subspace identification in terms of reciprocal processes defined on a finite interval. We discuss modeling of textures in the framework of acausal stochastic systems and stochastic realization theory.
The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial

Ja-Won Koo,Mun Young Chang,Sung-Cheol Yun,Tae Su Kim,Soo-Keun Kong,Jong Woo Chung,Eui-Kyung Goh

DOI: https://doi.org/10.1007/s00405-015-3821-4

2015-11-11

Abstract:Steroids are currently the most frequently accepted agents for idiopathic sudden sensorineural hearing loss (ISSNHL). However, the therapeutic effect of steroids is not always satisfactory. In this pilot study, we evaluated whether systemic treatment with Ginkgo biloba extract (EGb761) has an additive therapeutic effect in patients receiving a systemic steroid due to ISSNHL. A multicenter, randomized, double-blind clinical trial was performed. Fifty-six patients with ISSNHL were allocated to either EGb761 or placebo. In both groups, methylprednisolone was administered for 14 days. EGb761 was infused intravenously for 5 days in the EGb761 group, while the same amount of normal saline was infused in the placebo group. For the efficacy evaluation, pure-tone audiometry, speech audiometry, tinnitus handicap inventory (THI) and short form-36 health (SF-36) survey outcomes were obtained before administration and on days 3, 5, 14 and 28 of administration. Twenty-four patients in each group completed the study protocol. There was no difference in hearing loss between the two groups before treatment. At day 28, air conduction threshold values in the placebo and EGb761 groups were 34.63 ± 28.90 and 23.84 ± 25.42 dB, respectively (p = 0.082). Speech discrimination scores in the placebo and EGb761 groups were 69.17 ± 40.89 and 87.48 ± 28.65 %, respectively (p = 0.050). THI and SF-36 scores in the placebo and EGb761 groups were similar. Although a combination of steroid and EGb761 for initial treatment did not show better pure tone threshold, compared with steroid alone, speech discrimination was significantly improved in combination therapy. Further studies will be needed to know if addition of EGb761 actually improves the outcome of ISSNHL treatment.

otorhinolaryngology
Epidemiology of stroke in relation to the cardiovascular disease complex.

R. Stallones

Abstract:
[Efficacy of Betahistine Mesilate Combined with Flunarizine Hydrochloride for Treating Tinnitus].

Fu-rong Ma,Ying Xin,Yi-ming Zhao,Jing-qiao Lü

DOI: https://doi.org/10.3760/j.issn:1673-0860.2006.04.009

2006-01-01

Abstract:OBJECTIVETo determine whether Betahistine mesilate is effective in treating tinnitus.METHODSRandomized, prospective, double-blind, controlled trial was used in our study. The study group consisted of 60 adult patients who consulted our outpatient clinic complaining of subjective tinnitus, excluded objective tinnitus and the patients who had tinnitus caused by obvious diseases, such as outer and middle ear diseases. Thirty patients were given Betahistine mesilate and Flunarizine Hydrochloride as an experimental group, 30 patients were given Vitamin B6 and Flunarizine Hydrochloride as a control group. After a week of treatment the efficacy of the medicines in two groups was observed. Tinnitus questionnaire was performed before the treatment, and pure tone audiogram, tinnitus pitch and loudness matching were performed both in the beginning and at the end of the treatment.RESULTSCompletion of treatment, tinnitus loudness matching assessment showed that the efficacy of the Betahistine mesilate group was better then the control group. The efficacy of treatment was respectively 65.5% by per protocol (PP) and 63.3% by intend to treat (ITT) in the Betahistine mesilate group and 39.3% by PP and 36.7% by ITT in the control group. The difference of tinnitus loudness improvement rate between the experimental group and control group was statistically significant. But the subjective tinnitus improvement rate showed no difference between two groups. There were not serious side effects in the two groups.CONCLUSIONSBetahistine mesilate can be a choice for tinnitus treatment clinically. Further studies of larger series and placebo-controlled trial are needed.
Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.

Wu-Fang Zhang,Yun-Long Tan,Xiang-Yang Zhang,Raymond C K Chan,Hao-Ran Wu,Dong-Feng Zhou

DOI: https://doi.org/10.4088/JCP.09m05125yel

2011-01-01

Abstract:Objective: Free radicals may be involved in the pathogenesis of tardive dyskinesia (TD). Extract of Ginkgo biloba (EGb) is a potent antioxidant possessing free radical-scavenging activities. The aim of the study was to evaluate the efficacy of EGb-761, a standardized extract given in capsule form, in treating TD in schizophrenia patients. Method: Inpatients with DSM-IV-diagnosed schizophrenia and TD (n =157) in a mainland China Veterans Affairs psychiatric hospital were randomly assigned to 12 weeks of treatment with either EGb-761, 240 mg/d (n=78) or a placebo (n=79) in a double-blind manner. Primary outcome measures were (1) change from baseline in the Abnormal Involuntary Movement Scale (AIMS) score and (2) proportion of patients with a 30% reduction in their AIMS total score at week 12. Secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS) and cognitive performance as measured by the Continuous Performance Test-37 Version and the 3-card Stroop task. Patients were recruited for the study between December 2006 and May 2007. Results: Of the 157 patients who were randomly assigned, 152 (96.8%) completed the study. EGb-761 treatment significantly decreased the AIMS total score in patients with TD compared to those who were given a placebo (2.13 +/- 1.75 vs -0.10 +/- 1.69; P<.0001), with 40 (51.3%) and 4 (5.1%) patients achieving response in the EGb-761 and placebo treatment groups, respectively. There were no between-group differences in the PANSS total score or cognitive measures from baseline to week 12. Conclusions: EGb-761 appears to be an effective treatment for reducing the symptoms of TD in schizophrenia patients, and improvement may be mediated through the well-known antioxidant activity of this extract.
A Double-Blind, Placebo-Controlled Trial of Extract of Ginkgo Biloba Added to Haloperidol in Treatment-Resistant Patients with Schizophrenia.

XY Zhang,DF Zhou,PY Zhang,GY Wu,JM Su,LY Cao

DOI: https://doi.org/10.4088/jcp.v62n1107

2001-01-01

Abstract:BACKGROUND:Many studies have indicated that excess free radical formation may be involved in the pathogenesis of patients with schizophrenia. Some investigators suggested that the use of free radical scavengers might provide improvement in schizophrenia. The aim of this study was to determine the effectiveness and to evaluate the side effects of extract of Ginkgo biloba (EGb) plus haloperidol in chronic, treatment-resistant inpatients with schizophrenia.METHOD:One hundred nine patients meeting DSM-III-R criteria for schizophrenia completed a double-blind, placebo-controlled, parallel-group study of EGb plus haloperidol. Fifty-six of the patients were randomly assigned to receive a fixed dose of 360 mg/day of EGb plus a stable dose of haloperidol, 0.25 mg/kg/day, and 53 were assigned to receive placebo plus the same dose of haloperidol for 12 weeks. Patients were assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS) at baseline, week 6, and week 12 and the Treatment Emergent Symptom Scale (TESS) for side effects at week 12.RESULTS:There was a significant reduction in both groups in BPRS total score after 12 weeks of treatment (p < .05). However, a significant reduction in total SAPS and SANS scores was noted in the EGb group (p < .05), but not in the placebo group. There was a lower SAPS total score in the EGb group than in the placebo group at the end of 12 weeks of treatment (p < .05). Of those treated with EGb plus haloperidol, 57.1% were rated as responders as compared with only 37.7% of those receiving placebo plus haloperidol when assessed by the SAPS (chi2 = 4. 111, p = .043). After 12 weeks of treatment, TESS subscore 1 (behavioral toxicity) and subscore 3 (symptoms of nerve system) were significantly decreased in the EGb group compared with the placebo group (p < .05).CONCLUSION:EGb treatment may enhance the effectiveness of antipsychotic drugs and reduce their extrapyramidal side effects.
The curative effect of standardized Ginkgo Bilobaete Extract(Egb 761) on peripheral vestibular vertigo

戴春富,崔勇,赵燕玲,王正敏

DOI: https://doi.org/10.3969/j.issn.1671-2420.2002.01.005

2002-01-01

Abstract:Purpose To verify the curative effect of standardized Ginkgo Bilobate Extract (Egb 761) on peripheral vestibular vertigo. Methods 60 patients with peripheral vestibular vertigo were divided into two groups, and the group on test and the control group were given Egb 761or Betahistine respectively for 12 weeks. Results The frequency and duration,and the overall symptoms of vertigo at the end of the 12th week of the group on test are significantly betler than those of the control group after Wilcoxon Rank Sum test (p 0.05),After 12 weeks' treatment,no significant difference of total effective rate was found between the two groups,but the significant effective rate of the group on test is 44.8%(13/29), significantly higher than the control group' s 12.9%(4/31 ),x2 = 7.520,p = 0.006. Conclusion standardized Ginkgo Bilobate Extract can be effectively used on the treatment of peripheral (vestibular vertigo. At the same time, linnitus and nausea can get amelioration.The total effective rate of treatment is 77.4% ,among which significant effective rate is 44.8% .
Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial

R Ihl,M Tribanek,N Bachinskaya,GOTADAY Study Group

DOI: https://doi.org/10.1055/s-0031-1291217

Pharmacopsychiatry

Abstract:Introduction: A 24-week randomised controlled trial was conducted to assess the efficacy of a 240 mg once-daily preparation of Ginkgo biloba extract EGb 761® in 404 outpatients ≥ 50 years diagnosed with mild to moderate dementia (SKT 9-23), Alzheimer's disease (AD) or vascular dementia (VaD), with neuropsychiatric features (NPI total score ≥ 5). Methods: Separate analyses were performed for diagnostic subgroups (probable or possible AD; VaD). Results: 333 patients were diagnosed with AD and 71 with VaD. EGb 761® treatment was superior to placebo with respect to the SKT total score (drug-placebo differences: 1.7 for AD, p<0.001, and 1.4 for VaD, p<0.05) and the NPI total score (drug-placebo differences: 3.1 for AD, p<0.001 and 3.2 for VaD, p<0.05). Significant drug-placebo differences were found for most secondary outcome variables with no major differences between AD and VaD subgroups. Rates of adverse events in EGb 761® and placebo groups were essentially similar. Conclusion: EGb 761® improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia.
Efficacy and safety of Ginkgo biloba extract as an adjuvant in the treatment of Chinese patients with sudden hearing loss: a meta-analysis

Chao Yuan,Huan Zhang,Cuicui Sun,Kai Zhang

DOI: https://doi.org/10.1080/13880209.2023.2190782

2023-04-01

Pharmaceutical Biology

Abstract:Ginkgo biloba Linn (Ginkgoaceae) [leaves extract (GBE)] is authorized for the treatment of sudden hearing loss (SHL); however, its clinical feasibility in SHL has not been thoroughly investigated. To evaluate the efficacy and safety of adjuvant GBE in the treatment of SHL. We used PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, Chinese Scientific Journal Database, China Biomedical Database for literature research, starting from inception to 30 June 2022. The key terms: Ginkgo biloba extract, Sudden Sensorineural Deafness. This meta-analysis contained randomized controlled trials that compared the safety and efficacy of the combination of GBE and general treatments (GT) with GT alone for SHL. The extracted data were analyzed using Revman5.4 software with risk ratio (RR), 95% confidence intervals (CI) and mean difference (MD). Our meta-analysis included 27 articles with a total of 2623 patients. The results revealed that the effects of GBE adjuvant therapy was superior than GT (total effective rate: RR = 1.22, 95% CI: 1.18–1.26, p < 0.00001), the pure tone hearing threshold ( MD = 12.29, 95% CI: 11.74–12.85, p < 0.00001) and hemorheology indexes (whole blood high shear viscosity: MD = 1.46, 95% CI: 0.47–2.44, p = 0.004) after treatment were significantly improved compared to non-treatment, while there was no significant difference as for hematocrit (red blood cells) ( MD = 4.15, 95% CI: −7.15–15.45, p = 0.47). The efficacy of GBE + GT for the treatment of SHL may be more promising than GT alone.

pharmacology & pharmacy,medical laboratory technology,plant sciences
An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing.

Ruben D. Restrepo,S. Dickson,J. L. Rau,Douglas S Gardenhire

Respiratory Care

Abstract:BACKGROUND The literature lacks comparative data on nebulizer aerosol delivered via mask versus T-piece, to spontaneously breathing pediatric subjects. PURPOSE To compare total inhaled drug mass delivered via standard pediatric aerosol mask versus via T-piece, with increasing distance. METHODS We used a sample of 5 nebulizers, operated under manufacturers' conditions, with a standard pediatric aerosol mask and with a T-piece capped at one end, at 0 cm, 1 cm, and 2 cm from an inhalation filter placed at the inlet of a pediatric test lung. Inhaled drug mass was analyzed with spectrophotometry. Aerosol particle size was measured separately from the breathing simulations, using a laser particle sizer to determine fine-particle mass (particles < 4.7 mum) and fine-particle fraction as percent of total mass. The fine-particle fraction was used to estimate the fine-particle mass. RESULTS The mean + SD values for inhaled drug mass as a percentage of nominal dose, at 0 cm, 1 cm, and 2 cm, with the mask were 2.88 + 0.79%, 1.61 + 0.65%, and 1.3 + 0.42%, respectively, and with the T-piece were 4.14 + 1.37%, 3.77 + 1.04%, and 3.47 + 0.64%, respectively. There was a statistically greater inhaled drug mass with T-piece than with mask, overall (p < 0.01), and a significant decrease with mask or T-piece as distance increased (p < 0.01). The difference between mask and T-piece for inhaled drug mass at 2 cm was statistically significant (p < 0.018). The mean + SD values for fine-particle mass estimated as a percentage of total drug mass at 0, 1, and 2 cm, with the mask were 1.39 + 0.36%, 0.78 + 0.29%, and 0.64 + 0.20%, respectively, and with the T-piece were 2.1 + 0.63%, 1.84 + 0.45%, and 1.71 + 0.27%, respectively. CONCLUSION Inhaled drug mass was greater with T-piece than with a standard pediatric aerosol mask under the conditions studied.
Efficacy and Safety of Standardized Ginkgo Biloba L. Leaves Extract As an Adjuvant Therapy for Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-Analysis

Xia Si,Zhiying Yu,Xiaolei Ren,Lin Huang,Yufei Feng

DOI: https://doi.org/10.1016/j.jep.2021.114587

IF: 5.195

2022-01-01

Journal of Ethnopharmacology

Abstract:Ethnopharmacological relevance: Ginkgo biloba L. has been used for medical purposes in China for centuries. Standardized Ginkgo biloba L. leaves extract (GBE) is a widely used botanical drug which displays a variety of pharmacological effects against sudden sensorineural hearing loss (SSNHL). Aim of the study: To evaluate the efficacy and safety of GBE as an adjuvant therapy, administered with corticosteroids, for the initial management of patients with SSNHL. Materials and methods: We searched seven databases for randomized clinical trials (RCTs) comparing GBE plus corticosteroids with corticosteroids alone for SSNHL treatment. Data analysis was carried out by Review Manager 5.4 and Stata 16.0 software. The study was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. We subsequently evaluated the certainty of evidence using the GRADE (Grading of Recommendation Assessment, Development and Evaluation) approach. Results: A total of 11 RCTs involving 1069 patients were included. Meta-analysis indicated that the clinical cure rate (RR = 1.33, 95% CI = 1.12 to 1.58, P = 0.001) and total effective rate (RR = 1.24, 95%CI = 1.17 to 1.31, P < 0.001) in SSNHL patients receiving GBE plus corticosteroids was superior to patients receiving corticosteroids alone. After treatment, pure tone average (PTA) improvement of observation group was better than that in the control group (WMD = 10.33, 95%CI = 6.46 to 14.21, P < 0.001). The levels of whole blood high shear viscosity (WMD = 0.93, 95%CI = 0.28 to 1.59, P = 0.005), whole blood medium shear viscosity (WMD = 0.53, 95%CI = 0.11 to 0.95, P = 0.01), whole blood low shear viscosity (WMD = 1.26, 95%CI = 0.80 to 1.72, P < 0.001), plasma viscosity (WMD = 0.19, 95%CI = 0.09 to 0.30, P < 0.001) and fibrinogen (WMD = 0.80, 95%CI = 0.25 to 1.35, P = 0.004) were lower than those in the control group. There was no significant difference in the change of hematokrit between two groups (WMD = 4.23, 95%CI=-0.54 to 8.99, P = 0.08). GBE was generally well tolerated, and there was no significant difference in the incidence of adverse reactions between two groups (RR = 1.01, 95%CI = 0.57 to 1.79, P = 0.97). Conclusion: The results of the current study suggested that GBE might be effective and promising as an adjuvant to corticosteroids in the initial treatment of moderate to profound SSNHL. However, the GRADE assessment indicated that the overall strength of evidence was not high. Further studies with high methodological quality and low risk of bias are needed to confirm the positive results.
Efficacy of different protocols of transcranial magnetic stimulation for the treatment of tinnitus: Pooled analysis of two randomized controlled studies

B Langguth,M Landgrebe,E Frank,M Schecklmann,P G Sand,V Vielsmeier,G Hajak,T Kleinjung

DOI: https://doi.org/10.3109/15622975.2012.708438

Abstract:Objectives: Tinnitus is related to alterations in neuronal activity of auditory and nonauditory brain areas. Targeted modulation of these areas by repetitive transcranial magnetic stimulation (rTMS) has been proposed as a new therapeutic approach for chronic tinnitus. Methods: Two randomized, double-blind, parallel-group, controlled clinical trials were performed subsequently and pooled for analysis. A total of 192 tinnitus patients were randomly allocated to receive 10 stimulation sessions of either sham rTMS, PET-based neuronavigated 1 Hz rTMS, 1Hz r TMS over the left auditory cortex, or combined 20 Hz rTMS over the left frontal cortex, followed by 1 Hz rTMS over the left auditory cortex. Results: rTMS treatment was well tolerated and no severe side effects were observed. All active rTMS treatments resulted in significant reduction of the TQ as compared to baseline. The comparison between treatment groups failed to reach significant differences. The number of treatment responders was higher for temporal rTMS(38%) and combined frontal and temporal rTMS (43%), as compared to sham (6%). Conclusions: This large study demonstrates the safety and tolerability of rTMS treatment in patients with chronic tinnitus. While the overall effect did not prove superior to placebo, secondary outcome parameters argue in favour of the active stimulation groups, and specifically the combined frontal and temporal rTMS protocol.
Survey on the Effectiveness of Dietary Supplements to Treat Tinnitus

Claudia Coelho,Richard Tyler,Haihong Ji,Eveling Rojas-Roncancio,Shelley Witt,Pan Tao,Hyung-Jin Jun,Tang Chuan Wang,Marlan R. Hansen,Bruce J. Gantz

DOI: https://doi.org/10.1044/2016_aja-16-0021

2016-01-01

American Journal of Audiology

Abstract:Purpose: We surveyed the benefit of dietary supplements to treat tinnitus and reported adverse effects.Method: A website was created for people with tinnitus to complete a variety of questions.Results: The 1,788 subjects who responded to questionnaires came from 53 different countries; 413 (23.1%) reported taking supplements. No effect on tinnitus was reported in 70.7%, improvement in 19.0%, and worsening in 10.3%. Adverse effects were reported in 6% (n = 36), including bleeding, diarrhea, headache, and others. Supplements were reported to be helpful for sleep: melatonin (effect size, d = 1.228) and lipoflavonoid (d = 0.5244); emotional reactions: melatonin (d = 0.6138) and lipoflavonoid (d = 0.457); hearing: Ginkgo biloba (d = 0.3758); and concentration Ginkgo biloba (d = 0.3611). The positive, subjective reports should be interpreted cautiously; many might have reported a positive effect because they were committed to treatment and expected a benefit. Users of supplements were more likely to have loudness hyperacusis and to have a louder tinnitus.Conclusions: The use of dietary supplements to treat tinnitus is common, particularly with Ginkgo biloba, lipoflavonoids, magnesium, melatonin, vitamin B12, and zinc. It is likely that some supplements will help with sleep for some patients. However, they are generally not effective, and many produced adverse effects. We concluded that dietary supplements should not be recommended to treat tinnitus but could have a positive outcome on tinnitus reactions in some people.

Endoscopic biliary recanalization by using a needle catheter in patients with complete ligation or stricture of the bile duct: safety and feasibility of a novel technique (with videos).

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.

Ginkgo biloba Extract EGb 761® or Pentoxifylline for the Treatment of Sudden Deafness: A Randomized, Reference-controlled, Double-blind Study

AN EVALUATION OF PULP SLUDGE AS A COMPONENT IN MANUFACTURED TOPSOILS

Pharmacologic treatments in preclinical tinnitus models with special focus on Ginkgo biloba leaf extract EGb 761®

Protective Effects of Ginkgo biloba Extract EGb 761 against Noise Trauma-Induced Hearing Loss and Tinnitus Development

Preventive Effects of Ginkgo-Extract EGb 761® on Noise Trauma-Induced Cochlear Synaptopathy

Correction: The Critical Role of Partially Exposed N-Terminal Valine Residue in Stabilizing GH10 Xylanase from Bacillus sp.NG-27 under Poly-Extreme Conditions

Reciprocal realization and modeling of textured images

The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial

Epidemiology of stroke in relation to the cardiovascular disease complex.

[Efficacy of Betahistine Mesilate Combined with Flunarizine Hydrochloride for Treating Tinnitus].

Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.

A Double-Blind, Placebo-Controlled Trial of Extract of Ginkgo Biloba Added to Haloperidol in Treatment-Resistant Patients with Schizophrenia.

The curative effect of standardized Ginkgo Bilobaete Extract(Egb 761) on peripheral vestibular vertigo

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial

Efficacy and safety of Ginkgo biloba extract as an adjuvant in the treatment of Chinese patients with sudden hearing loss: a meta-analysis

An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing.

Efficacy and Safety of Standardized Ginkgo Biloba L. Leaves Extract As an Adjuvant Therapy for Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-Analysis

Efficacy of different protocols of transcranial magnetic stimulation for the treatment of tinnitus: Pooled analysis of two randomized controlled studies

Survey on the Effectiveness of Dietary Supplements to Treat Tinnitus